Amenze Oriaifo, MD
Glaucoma Specialist · Austin, TXNPI 1629496641
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,740 of the $17,712 with a category attached, or 60.6%. 25 manufacturers reported payments, led by AbbVie at 53.2% of the total. Among glaucoma specialist clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 281 payments — averaging $63.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$9K
- Alcon$2K
- Bausch & Lomb Americas Inc.$1K
- NEW World Medical,inc.$806
- Sight Sciences, Inc.$800
- Ocular Therapeutix, Inc.$679
- plus $3K from 19 others
What the payments were for
- Consulting fees$1,1006%
- Speaking & faculty fees$4,95028%
- Travel & lodging$8355%
- Food & beverage$10,74061%
- Education$240%
- Other$640%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 92 | $9,421 |
| Alcon | 27 | $1,974 |
| Bausch & Lomb Americas Inc. | 45 | $1,189 |
| NEW World Medical,inc. | 11 | $806 |
| Sight Sciences, Inc. | 13 | $800 |
| Ocular Therapeutix, Inc. | 31 | $679 |
| Rxsight Inc | 9 | $612 |
| Glaukos Corporation | 6 | $550 |
| Amgen(2 entities) | 17 | $384 |
| Ellexiscience | 1 | $331 |
| Regeneron | 1 | $150 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $143 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $127 |
| Biotissue Holdings Inc. | 2 | $107 |
| Sun Pharmaceutical Industries Inc. | 3 | $72 |
| Novartis | 3 | $66 |
| Carl Zeiss Meditec USA, Inc. | 1 | $64 |
| Tarsus Pharmaceuticals, Inc. | 2 | $53 |
| Astellas Pharma US Inc | 2 | $52 |
| Aerie Pharmaceuticals, Inc. | 2 | $37 |
| Oyster Point Pharma, Inc. | 1 | $31 |
| Omeros Corporation | 1 | $20 |
| Thea Pharma Inc. | 1 | $18 |
| Tearlab Corp | 1 | $15 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VUITY$5,796
- Hydrus Microstent$553
- OMNI(R) SURGICAL SYSTEM (US)$547
- VYZULTA$516
- RXSIGHT CONTACT LENS$425
- RXSIGHT INJECTOR CARTRIDGE$425
- RXSIGHT INJECTOR HANDPIECE$425
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$425
- LIGHT ADJUSTABLE LENS (LAL)$425
- Clareon$256
- Kahook Dual Blade$252
- Clearpath$252
- Ahmed Glaucoma Valve$252
- Streamline$252
- Via360$252
- LenSx$249
- iStent inject Trabecular Micro-Bypass Stent System$247
- DURYSTA$240
- EYLEA HD$150
- MIEBO$149
How this compares
$17,712 in reported general payments places this provider in the 90th percentile of 31 glaucoma specialist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 507 | $260,887 |
| VyzultaLatanoprostene Bunod | 282 | $130,456 |
| CombiganBrimonidine Tartrate/Timolol | 142 | $72,648 |
| RestasisCyclosporine | 49 | $49,355 |
| Alphagan PBrimonidine Tartrate | 89 | $48,207 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 153 | $38,503 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 185 | $36,826 |
| Brimonidine Tartrate | 506 | $33,142 |
| RocklatanNetarsudil Mesylat/Latanoprost | 56 | $25,889 |
| RhopressaNetarsudil Mesylate | 39 | $24,314 |
| Travoprost | 127 | $18,311 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 946 | $16,584 |
| XiidraLifitegrast | 13 | $16,322 |
| Latanoprost | 1,462 | $15,824 |
| Cyclosporine | 27 | $14,185 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $9,421 | $431,098787 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $1,189 | $146,778295 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $37 | $50,20395 claims |
| AlconSimbrinza | $1,974 | $38,503153 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $143 | $2,31211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 31 glaucoma specialist providers in Texas.
Other glaucoma specialist in Austin
- Irina VoloskoAustin$11K
- Robert MarquisAustin$3K
- Shivani KamatDallas$164K
- Robert FeldmanHouston$31K
- David LeeHouston$17K
- Nicholas GurneyFt Worth$13K
- Patrick WuHouston$11K
- Logan VincentTyler$5K
- Thao ThachGarland$4K
- Elza RachidHouston$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.